Wells Fargo Van Kasper Growth Stock Conference The Wyndham Emerald Plaza San Diego, California
June 18, 2001 - 9:30 a.m.
Amylin Pharmaceuticals, Inc.
Safe Harbor Statement
Current Pipeline Status
Diabetes: Worldwide Estimates and Projections
Diabetes: A Serious, Progressive Disease
Diabetes: Devastateing Clinical and Economic Consequences
Diabetes: Inadequately Treated and Growing Rapidly
Lessons from Landmark Diabetes Studies: Intervention Works
Lessons from Landmark Diabetes Studies: Intervention Works, But at a Price #1
Lessons from Landmark Diabetes Studies: Intervention Works, But at a Price #2
SYMLIN™ (pramlintide acetate) Overview
SYMLIN Patient Focus People With Diabetes Who Use Insulin
SYMLIN™ (pramlintide acetate) Glucose and Weight Effect at One Year
SYMLIN Market Opportunity North America and Western Europe
SYMLIN Market Opportunity United States
SYMLIN Market Opportunity: US Insulin Prescriptions Highly Concentrated
SYMLIN Commercial Operations Sales Planning Model
SYMLIN Commercial Operations Experienced Core Commercial Team
Amylin the Hormone Medical Education Program
Upcoming Medical Meetings
AC2993 (synthetic exendin-4) Overview
AC2993 (synthetic exendin-4) Patient Focus
AC2993 (synthetic exendin-4)
AC2993 LAR
Potential Diabetes Target Markets
AC3056
Expanding the Pipeline
Financial Overview
Goals for 2001